scholarly journals ROX Index as a Predictor of Intubation Risk and 28-Day Mortality in COVID-19 Patients with Acute Respiratory Distress Syndrome

2022 ◽  
Vol 3 (1) ◽  
Author(s):  
Putra Kurnia Nugraha ◽  
Arie Utariani ◽  
Philia Setiawan ◽  
Bambang Pujo Semedi
Keyword(s):  
Acute Respiratory Distress Syndrome ◽  
Respiratory Distress Syndrome ◽  
Respiratory Distress ◽  
Distress Syndrome ◽  
Proportional Hazards ◽  
Rapid Assessment ◽  
Cox Proportional Hazards ◽  
Main Concern ◽  
High Flow Nasal Cannula ◽  
Proportional Hazards Regression

Background: The main concern when treating COVID-19 acute respiratory distress syndrome (ARDS) during high flow nasal cannula (HFNC) is delayed intubation, thus increasing the risk of prior mortality. This study aims to analyze the prognostic ability of the Respiratory Rate Oxygenation (ROX) index as a predictor for intubation and 28-days mortality in COVID-19 patients. Methods: A retrospective analysis of COVID-19 patients admitted to Intensive Care Unit (ICU) Dr. Soetomo General Hospital in Surabaya from July to December 2020 with ARDS. The ROX indices were recorded at the 1st hour, 2nd, 4th, 6th, 12th, 18th, 24th, and 48th hours of treatment in ICU with HFNC. Identification of ROX association with HFNC failure led to intubation and 28-days mortality was through Cox proportional hazards regression. The most specific cut-off of the ROX index for predicting intubation and 28-days mortality was assessed. Result: Among 78 patients who met the inclusion criteria, 26 (33.3%) patients required intubation. Out of 26 patients, six patients were extubated and had survived. The 28-days mortality rate is 20 (25.6%) patients. The ROX index at 12th hours (ROX-12) ≤ 4.85 (AUC 0.857; p<0.001; HR 4.7) and the ROX index at 48th hours (ROX-48) ≤ 5.68 (AUC 0.858; p<0.001; HR 5.4) can accurately predict the need for intubation. ROX-12 ≤ 4.745 is a predictor of 28-days mortality (AUC 0.85, p<0.001; HR 10.2). Conclusion: ROX index predicts the risk of intubation and 28-days mortality especially ROX-12 and ROX-48. Utilization of ROX index for rapid assessment of the respiratory deterioration in COVID-19 is recommended.

scholarly journals High flow nasal cannula oxygenation in COVID-19 related acute respiratory distress syndrome: a safe way to avoid endotracheal intubation?

2021 ◽  
Vol 15 ◽  
pp. 175346662110195
Author(s):  
Agathe Delbove ◽  
Ambroise Foubert ◽  
François Mateos ◽  
Tiphaine Guy ◽  
Marie Gousseff
Keyword(s):  
Acute Respiratory Distress Syndrome ◽  
Hospital Mortality ◽  
Respiratory Distress Syndrome ◽  
Respiratory Distress ◽  
Healthcare Workers ◽  
Distress Syndrome ◽  
High Flow ◽  
Nasal Cannula ◽  
Arterial Oxygen ◽  
High Flow Nasal Cannula

Backgrounds: High flow nasal cannula (HFNC) is an alternative therapy for acute respiratory distress syndrome (ARDS) due to coronavirus disease 2019 (COVID-19). This study aimed first to describe outcomes of patients suffering from COVID-19-related ARDS treated with HFNC; secondly to evaluate safety of HFNC (patients and healthcare workers) and compare patients according to respiratory outcome. Methods: A retrospective cohort was conducted in French general hospital intensive care unit (ICU). Patients were included if receiving HFNC for hypoxemia (saturation pulse oxygen (SpO2) <92% under oxygen ⩾6 L/min) associated with ARDS and positive SARS-CoV-2 polymerase chain reaction (PCR). Main clinical characteristics and outcomes are described in patients: (a) with do not intubate order (HFNC-DNIO); (b) who did not need intubation (HFNC-only); and (c) eventually intubated (HFNC-intubation). Medians are presented with (1st–3rd) interquartile range. Results: From 26 February to 30 June 2020, 46 patients of median age 75 (70–79) years were included. In the HFNC-DNIO group ( n = 11), partial arterial oxygen pressure (PaO2)/inhaled fraction of oxygen (FiO2) ratio median worst PaO2/FiO2 ratio was 109 (102–172) and hospital mortality was 54.5%. Except the HFNC-DNIO patients ( n = 35), 20 patients (57%) were eventually intubated (HFNC-intubation group) and 15 were only treated by HFNC (HFNC-only). HFNC-intubation patients presented higher worst respiratory rates per minute in ICU [37 (34–41) versus 33 (24–34) min, p < 0.05] and worsened ICU admission PaO2/FiO2 ratios [121 (103–169) versus 191 (162–219), p < 0.001] compared with HFNC-only patients. Hospital mortality was 35% ( n = 7/20) in HFNC-intubation group, 0% in HFNC-only group with a global mortality of these two groups of 20% ( n = 7/35). Among tests performed in healthcare workers, 1/12 PCR in symptomatic healthcare workers and 1.8% serologies in asymptomatic healthcare workers were positive. After review of each case, COVID-19 was likely to be acquired outside hospital. Conclusions: HFNC seems to be useful for COVID-19-related ARDS and safe for healthcare workers. ARDS severity with PaO2/FiO2 <150 associated with respiratory rate >35/min could be regarded as a predictor of intubation. The reviews of this paper are available via the supplemental material section.

scholarly journals Early Improvement of Acute Respiratory Distress Syndrome in Patients with COVID-19: Insights from the Data of ICU Patients in Chongqing, China

2020 ◽  
Author(s):  
Zhu Zhan ◽  
Xin Yang ◽  
Hu Du ◽  
Chuanlai Zhang ◽  
Yuyan Song ◽  
...  
Keyword(s):  
Acute Respiratory Distress Syndrome ◽  
Intensive Care ◽  
Respiratory Distress Syndrome ◽  
Respiratory Distress ◽  
Distress Syndrome ◽  
Independent Predictor ◽  
Case Fatality ◽  
High Flow Nasal Cannula ◽  
Icu Patients ◽  
Early Improvement

Acute respiratory distress syndrome (ARDS) may be the main cause of death in patients with coronavirus disease 2019 (COVID-19). Herein, we retrospect clinical features, outcomes and ARDS characteristics of 75 intensive care unit (ICU) patients with COVID-19 in Chongqing, China. We found a 5.3% case fatality rate of the ICU patients in Chongqing. 93% patients developed ARDS during the intensive care, and more than half were moderate. However, most of the patients (55%) supported with high flow nasal cannula (HFNC) oxygen therapy, but not mechanical ventilation. Nearly one third of patients with ARDS got an early improvement (eiARDS), and the rate is much higher than the other causes of ARDS in a previous study. Patients with eiARDS had a higher survival rate and lower length of ICU stay. The age (< 55 years) is an independent predictor for the eiARDS, and stratification of COVID-19 patients by age is recommended.

scholarly journals High-flow nasal cannula for Acute Respiratory Distress Syndrome (ARDS) due to COVID-19

2020 ◽  
Vol 15 ◽  
Author(s):  
Carolina Panadero ◽  
Araceli Abad-Fernández ◽  
Mª Teresa Rio-Ramírez ◽  
Carmen Maria Acosta Gutiérrez ◽  
Mariara Calderón-Alcalá ◽  
...  
Keyword(s):  
Acute Respiratory Distress Syndrome ◽  
Respiratory Distress Syndrome ◽  
Respiratory Distress ◽  
Distress Syndrome ◽  
High Flow ◽  
Nasal Cannula ◽  
Intubation Rate ◽  
High Flow Nasal Cannula ◽  
Increased Risk ◽  
Bridge Therapy

Background: High-flow nasal cannula oxygen therapy (HFNC) has been shown to be a useful therapy in the treatment of patients with Acute Respiratory Distress Syndrome (ARDS), but its efficacy is still unknown in patients with COVID-19. Our objective is to describe its utility as therapy for the treatment of ARDS caused by SARS-CoV-2. Methods: A retrospective, observational study was performed at a single centre, evaluating patients with ARDS secondary to COVID-19 treated with HFNC. The main outcome was the intubation rate at day 30, which defined failure of therapy. We also analysed the role of the ROX index to predict the need for intubation.Results: In the study period, 196 patients with bilateral pneumonia were admitted to our pulmonology unit, 40 of whom were treated with HFNC due to the presence of ARDS. The intubation rate at day 30 was 52.5%, and overall mortality was 22.5%. After initiating HFNC, the SpO2/FiO2 ratio was significantly better in the group that did not require intubation (113.4±6.6 vs 93.7±6.7, p=0.020), as was the ROX index (5.0±1.6 vs 4.0±1.0, p=0.018). A ROX index less than 4.94 measured 2 to 6 h after the start of therapy was associated with increased risk of intubation (HR 4.03 [95% CI 1.18 – 13.7]; p=0.026).Conclusion: High-flow therapy is a useful treatment in ARDS in order to avoid intubation or as a bridge therapy, and no increased mortality was observed secondary to the delay in intubation. After initiating HFNC, a ROX index below 4.94 predicts the need for intubation.

COVID-19 – eine vaskuläre Systemerkrankung

2020 ◽  
Vol 49 (10) ◽  
pp. 418-421
Author(s):  
Christopher Werlein ◽  
Peter Braubach ◽  
Vincent Schmidt ◽  
Nicolas J. Dickgreber ◽  
Bruno Märkl ◽  
...  
Keyword(s):  
Acute Respiratory Distress Syndrome ◽  
Respiratory Distress Syndrome ◽  
Respiratory Distress ◽  
Distress Syndrome

ZUSAMMENFASSUNGDie aktuelle COVID-19-Pandemie verzeichnet mittlerweile über 18 Millionen Erkrankte und 680 000 Todesfälle weltweit. Für die hohe Variabilität sowohl der Schweregrade des klinischen Verlaufs als auch der Organmanifestationen fanden sich zunächst keine pathophysiologisch zufriedenstellenden Erklärungen. Bei schweren Krankheitsverläufen steht in der Regel eine pulmonale Symptomatik im Vordergrund, meist unter dem Bild eines „acute respiratory distress syndrome“ (ARDS). Darüber hinaus zeigen sich jedoch in unterschiedlicher Häufigkeit Organmanifestationen in Haut, Herz, Nieren, Gehirn und anderen viszeralen Organen, die v. a. durch eine Perfusionsstörung durch direkte oder indirekte Gefäßwandschädigung zu erklären sind. Daher wird COVID-19 als vaskuläre Multisystemerkrankung aufgefasst. Vor dem Hintergrund der multiplen Organmanifestationen sind klinisch-pathologische Obduktionen eine wichtige Grundlage der Entschlüsselung der Pathomechanismen von COVID-19 und auch ein Instrument zur Generierung und Hinterfragung innovativer Therapieansätze.

Sign in / Sign up

Export Citation Format

Share Document